REGULATORY
Keytruda to Get 17.5% Price Cut in February
November 13, 2019
US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) will see its price slashed by 17.5% in February next year under a Japanese re-pricing rule that is basically applied for drugs with better-than-projected sales, the Ministry of Health, Labor and Welfare (MHLW) said…

LATEST

November 14, 2019
Ajinomoto said on November 13 that it has entered into a subcontracting research and development agreement with Kanagawa Cancer Center to carry out joint research for the development of the next generation treatment and diagnosis of cancer.The joint research will…
November 14, 2019
Rohto Pharmaceutical, a leading Japanese maker of consumer eye care products, said on November 13 that it is buying Nitten Pharmaceutical in a bid to beef up its ophthalmic business. The companies entered into a share transfer agreement on the…
November 13, 2019
Four years after divesting its oncology franchise to Novartis in a global asset swap, GlaxoSmithKline is ratcheting up its drive to rebuild its presence in the competitive sector by plowing a massive R&D investment. Axel…
By Reiji Anasako

Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…

By Yoshinori Sagehashi

As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…

By Reiji Anasako

Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA